Clinical Applications

PuraMatrix® has demonstrated efficacy in multiple models for hemostasis (CE Mark approved, trade name PuraStat®), tissue regeneration, acute myocardial infarction, therapeutic protein and stem cell delivery, and CNS injury. PuraMatrix® can re-hydrate and provide mechanical support for disc height collapse in degenerated IVDs, anti-adhesion, polyp resection, and bone formation. PuraMatrix® has also been used to repair and restore visual function in the CNS after damage.

s-dots_14

Hemostasis

The ability to stop and control bleeding is critically important to all surgical procedures and to the practice of medicine in general. Based on the self-assembling peptide platform technology of PuraMatrix®, 3-D Matrix has obtained CE mark approval for the surgical hemostatic agent PuraStat®. PuraStat® gels upon blood contact and stops bleeding (hemostasis) via mechanical blocking of the bleeding site for diffuse bleeds while allowing full, transparent view of the target area. PuraStat® has a number of unique features that distinguish it from existing products.

Click here for peer-reviewed publications of PuraMatrix® (PuraStat®) as a surgical hemostatic agent.

News

Find out the most recent developments at 3-D Matrix

Learn More

Collaborations

Learn how PuraMatrix® can enhance your technology

Learn More

Publications

Review the strong body of literature utilizing PuraMatrix®

Learn More